1.Radioiodine Therapy For Differentiatd Thyroid Cancer.
Korean Journal of Nuclear Medicine 2000;34(4):265-275
The thyroid gland is an interesting endocrine organ where a spectrum of tumors with different behavior arise. At one end of spectrum there is differentiated thyroid carcinoma (DTC) with excellent prognosis, whereas at the other end of the spectrum is anaplastic thyroid cancer which has universally poor outcome. Radioiodine (I-131) therapy has been in use for the treatment of thyroid diseases since 1946. It was introduced by Seidlin et al. 1) Although the use of I-131 has been vouge for a long time, its use in therapy for well differentiated thyroid cancer is still controversial 2). This is because, thyroid cancers (TC) are generally slow growing tumors, with low mortality and normal spans of survival. To record recurrence and mortality, long term follow up studies over a period of two to three decades are needed to establish definite conclusions on the acceptable mode of treatment. The incidence of the disease being very low a large number of cases needed to establish a meaningful statistical data is lacking as most published reports deal with small series. Here again in the problem encountered are the differing protocols for treatment with I-131, the indications for treatment which may include or exclude ablation of residual thyroid tissue, cervical nodal and distal metastases. The dosage of I-131 used for ablation of residual thyroid tissue and metastatic disease also vary. The most reliable conclusion regarding I-131 treatment are obtained from studies reported on a large series of patients followed over a period of 2 decades or more from a single institute with a more or less unchanged protocol of management.
Follow-Up Studies
;
Humans
;
Incidence
;
Mortality
;
Neoplasm Metastasis
;
Prognosis
;
Recurrence
;
Thyroid Diseases
;
Thyroid Gland*
;
Thyroid Neoplasms*
2.Growth Hormone and Cardiovascular Disease.
Journal of Korean Society of Endocrinology 2004;19(6):616-622
No abstract available.
Cardiovascular Diseases*
;
Growth Hormone*
3.Growth Hormone Therapy in Adult Growth Hormone Defficiency.
Journal of the Korean Medical Association 1998;41(10):1063-1076
No abstract available.
Adult*
;
Growth Hormone*
;
Humans
4.Insulin-like growth factor I gene.
Journal of Korean Society of Endocrinology 1993;8(3):241-247
No abstract available.
Insulin-Like Growth Factor I*
5.Growth Hormone Therapy.
Journal of the Korean Medical Association 2002;45(2):206-215
The safe clinical practice of growth hormone(GH) replacement requires judgement of the overall GH status, however, there is no biological marker for this in adults. In addition, diverse actions of GH in healthy individuals render the assessment of optimal GH replacement difficult. As in other fields of clinical practice, strategies and protocols vary between centers, however, most physicians experienced in pituitary diseases agree that GH replacement should begin at low doses, and increased to the final maintenance dose. The adequacy replacement is best determined by combination of clinical response and serum IGF-I, level avoiding supraphysiological levels of this GH-dependent peptide. Actually, GH can reduce body fat and restore muscles, bones, and quality of life. Appropriate using of GH will elicit antiaging effects.
Adipose Tissue
;
Adult
;
Biomarkers
;
Growth Hormone*
;
Humans
;
Insulin-Like Growth Factor I
;
Muscles
;
Osteoporosis
;
Pituitary Diseases
;
Quality of Life
6.Assessment of Growth Hormone Status
Journal of Korean Society of Endocrinology 1996;11(3):263-267
No abstract available.
Growth Hormone
7.Clinical Applications of Growth Hormone: Focused to Antiaging Medicine.
Journal of the Korean Academy of Family Medicine 2004;25(6):447-454
No abstract available.
Growth Hormone*
8.Expression of Alpha Smooth Muscle Actin and Lysozyme in Various Glomerular Diseases.
Korean Journal of Pathology 1998;32(1):51-57
The cells of glomerular mesangium is composed mostly of intrinsic contractile mesangial cells and a few macrophages. Injury to the mesangium is central to many glomerular diseases. This study was aimed to evaluate and compare the expressions of alpha-smooth muscle actin (ASMA) and lysozyme in the mesangium of various human glomerular diseases and also of according to the severity of their progressions. We performed immunohistochemical and transmission electromicroscopic examinations in 51 cases of renal biopsy including 5 normal kidneys. The results were as follows; (1) ASMA staining was negligible in normal glomeruli. (2) Increased ASMA staining was observed in the mesangium of glomeruli from all specimens of primary glomerular disease, regardless of their diagnosis. (3) The staining intensity of ASMA in mesangium was mild in minimal change disease and membranous glomerulonephritis, and strong in focal segmental glomerulosclerosis (FSGS), diffuse mesangial hypercellularity, membranoproliferative glomerulonephritis (MPGN), and IgA nephropathy (IgAN). (4) The staining intensity of ASMA have no correlation with mesangial immune deposits. (5) The staining intensity of ASMA in mesangium was inversely correlated with the disease progression in FSGS and IgAN. (6) Glomeruli showing global or segmental sclerosis invariably lacked ASMA. (7) Compared with ASMA, the mesangial cells with lysozyme expression were very rare, even though it was in proportion to ASMA staining. Interstitial ASMA expression was confined to fibrotic area in various glomerular diseases. In conclusion, the expression of ASMA and lysozyme in mesangium are increased in a variety of glomerular diseases, regardless of disease entity. Their intensity was in proportion to the mesangial cell proliferation. In progressive glomerulonephritis, such as IgAN and FSGS, the increased expression of ASMA was prominent in the early lesion, and decreased with the progression of the glomerular sclerosis.
Actin Cytoskeleton
;
Actins*
;
Biopsy
;
Diagnosis
;
Disease Progression
;
Glomerular Mesangium
;
Glomerulonephritis
;
Glomerulonephritis, IGA
;
Glomerulonephritis, Membranoproliferative
;
Glomerulonephritis, Membranous
;
Glomerulosclerosis, Focal Segmental
;
Humans
;
Kidney
;
Macrophages
;
Mesangial Cells
;
Muramidase*
;
Muscle, Smooth*
;
Nephrosis, Lipoid
;
Sclerosis
9.The Last Fifty Years of Western Medicine in Korea: Korean Soceity of Anesthesiologists.
Woon Hyok CHUNG ; Sung Nyeun KIM
Journal of the Korean Medical Association 1997;40(8):1060-1065
No abstract available.
Korea*
10.A Case of Pemphigus Vegetans.
Sung Hun KIM ; Young Ho WOON ; Young Pio KIM
Korean Journal of Dermatology 1988;26(3):415-418
We experienced a 54-year-old female patient who had multiple vegetaing plaques and, peripherally, a few pustules in her both axillae. On the skin biopsy specimen of the vegetating plaque, it showed acanthosis, suprabasal acsntholysis, papillo-matosis, downward proliferation of the epidermis, and eosinophilic microroabscess in the epidermis. The indirect immunofluorescence study disclosed anto-antibody positive to intercellular substance of the lip of guinea pig, while direct. immuno-fluorescence of the perilesional skin reealed no specific findings. The skin lesion had improved with topical and systemic steroid therapy.
Animals
;
Axilla
;
Biopsy
;
Eosinophils
;
Epidermis
;
Female
;
Fluorescent Antibody Technique, Indirect
;
Guinea Pigs
;
Humans
;
Lip
;
Middle Aged
;
Pemphigus*
;
Skin